The FDA has accepted a BLA under its accelerated approval pathway from uniQure for ifezuntirgene inilparvovec to treat Huntington’s disease.

MVA-BN was originally developed in collaboration with the US Government as a smallpox vaccine. Credit: Bavarian Nordic. Bavarian Nordic has secured a four-year contract from the UK Government to ...

Fresenius and WuXi Biologics will work together to develop up to 37 biosimilar candidates targeting a range of therapeutic areas, giving the German company ample scope to bolster ...

Pelthos Therapeutics has agreed to merge with Castle Creek Biosciences to form a new biotechnology company that will focus on serious diseases affecting the skin.

Inovio has secured accelerated approval from the FDA for Voceryq to minimise the frequency of surgery in adults with recurrent respiratory papillomatosis (RRP).

The policy will allow licensed professionals to use certain wellness-focused peptides not approved by the FDA in their compounded medicines.

Gaelic Labs is eyeing competitive benefits from its 2025 acquisition of fellow Irish beta-lactams manufacturer and further expansion.

Reaction from the life sciences industry to the Autumn Budget was mixed, with the government opting for a more macro focus on business scaling.

This week's podcast features the Clinical Trials Arena team and GlobalData analysts who discuss the biggest study readouts from the ESMO Congress 2026.

Enthorin has signed an option-to-license deal with Rumi to advance ENT-7340 for FXS, as well as other intellectual and developmental disabilities.

Formation Bio has launched the Formation Bio Drug Development Accelerator Fund to broaden the company's clinical-stage medicines portfolio.